Analysts Offer Predictions for Humana Inc.’s FY2022 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUMGet Rating) – Stock analysts at Zacks Research reduced their FY2022 earnings estimates for Humana in a research report issued on Wednesday, November 16th. Zacks Research analyst D. Chatterjee now forecasts that the insurance provider will post earnings per share of $25.01 for the year, down from their previous forecast of $25.04. The consensus estimate for Humana’s current full-year earnings is $25.06 per share. Zacks Research also issued estimates for Humana’s Q1 2023 earnings at $8.04 EPS, Q3 2023 earnings at $6.62 EPS, FY2023 earnings at $27.80 EPS, Q1 2024 earnings at $8.44 EPS, Q2 2024 earnings at $8.56 EPS, Q3 2024 earnings at $8.08 EPS and FY2024 earnings at $31.16 EPS.

Several other brokerages also recently weighed in on HUM. Oppenheimer raised their price target on shares of Humana from $520.00 to $550.00 and gave the company an “outperform” rating in a research report on Friday, September 16th. Credit Suisse Group raised their price target on shares of Humana from $548.00 to $635.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Morgan Stanley raised their price target on shares of Humana from $549.00 to $620.00 and gave the company an “overweight” rating in a research report on Monday, October 31st. Truist Financial raised their price target on shares of Humana from $570.00 to $650.00 in a research report on Thursday, November 3rd. Finally, Royal Bank of Canada raised their price target on shares of Humana from $560.00 to $637.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Humana presently has an average rating of “Moderate Buy” and a consensus target price of $579.00.

Humana Price Performance

HUM stock opened at $529.90 on Friday. The firm has a 50 day moving average price of $513.67 and a 200-day moving average price of $482.58. Humana has a 52-week low of $351.20 and a 52-week high of $571.30. The firm has a market capitalization of $67.09 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 1.46 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.35.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be paid a dividend of $0.7875 per share. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, December 29th. Humana’s dividend payout ratio (DPR) is 14.29%.

Insider Activity at Humana

In related news, CFO Susan M. Diamond sold 5,623 shares of Humana stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $566.25, for a total transaction of $3,184,023.75. Following the transaction, the chief financial officer now owns 2,284 shares in the company, valued at approximately $1,293,315. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Humana news, CFO Susan M. Diamond sold 5,623 shares of the business’s stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $566.25, for a total value of $3,184,023.75. Following the sale, the chief financial officer now owns 2,284 shares in the company, valued at approximately $1,293,315. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO William Kevin Fleming sold 11,157 shares of the business’s stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $565.61, for a total transaction of $6,310,510.77. Following the completion of the sale, the chief accounting officer now owns 2,542 shares in the company, valued at approximately $1,437,780.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,161 shares of company stock worth $16,994,804. 0.39% of the stock is owned by corporate insiders.

Institutional Trading of Humana

Hedge funds have recently made changes to their positions in the business. Tcwp LLC purchased a new stake in shares of Humana during the 1st quarter valued at about $25,000. Jones Financial Companies Lllp purchased a new stake in shares of Humana during the 2nd quarter valued at about $29,000. WFA of San Diego LLC bought a new position in Humana during the 2nd quarter valued at about $30,000. Newbridge Financial Services Group Inc. grew its holdings in Humana by 42.3% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock valued at $35,000 after purchasing an additional 22 shares during the last quarter. Finally, Ritter Daniher Financial Advisory LLC DE bought a new position in Humana during the 2nd quarter valued at about $42,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.